FBXW2: A Potential Drug Target and Biomarker (G26190)

Target Name: FBXW2

NCBI ID: G26190

FBXW2

FBXW2: A Potential Drug Target and Biomarker

FBXW2, also known as F-box/WD repeat-containing protein 2, is a protein that has been identified as a potential drug target and biomarker. FBXW2 is a member of the F-box gene family, which is known for their role in the regulation of protein stability and localization. FBXW2 is expressed in a variety of tissues, including muscle, nerve, and heart, and has been shown to play a role in the development and progression of various diseases, including cancer.

The FBXW2 Protein

FBXW2 is a transmembrane protein that contains a unique farnesylated cysteine residue. This cysteine residue is important for the protein's stability and localization to the endoplasmic reticulum, where it can be targeted for degradation. FBXW2 has a calculated molecular weight of 41 kDa and a calculated pI of 5.3.

FBXW2 has been shown to play a role in the regulation of protein stability and localization by affecting the stability and localization of its own protein subunits. FBXW2 has been shown to interact with several other proteins, including the transcription factor, NF-Y1, which is known to play a role in the regulation of gene expression and protein stability.

FBXW2 and Cancer

FBXW2 has been shown to be involved in the development and progression of various cancers, including breast, ovarian, and colorectal cancers. Studies have shown that FBXW2 is expressed in the majority of human cancer tissues and that its expression is associated with the poor prognosis of these diseases.

One potential mechanism by which FBXW2 may contribute to cancer development is by regulating the activity of transcription factors, which are proteins that play a critical role in the regulation of gene expression and the expression of cancer-promoting genes. FBXW2 has been shown to interact with several transcription factors, including NF-Y1, which is known to play a role in the regulation of gene expression and protein stability.

Another potential mechanism by which FBXW2 may contribute to cancer development is by regulating the activity of microRNAs, which are small non-coding RNAs that play a critical role in the regulation of gene expression. FBXW2 has been shown to interact with several microRNAs, including hnRNPK, which is known to play a role in the regulation of gene expression and the expression of cancer-promoting genes.

FBXW2 as a Drug Target

FBXW2 has been shown to be a potential drug target by several mechanisms. First, studies have shown that FBXW2 is a good candidate for an anti-cancer drug because it is expressed in multiple cancer types and has been shown to contribute to the development and progression of these diseases. Second, studies have shown that FBXW2 is involved in the regulation of gene expression and protein stability, which are critical processes for the development and progression of cancer.

FBXW2 has also been shown to interact with several proteins that are known to play a critical role in the development and progression of cancer. For example, studies have shown that FBXW2 interacts with the transcription factor, NF-Y1, which is known to play a role in the regulation of gene expression and the expression of cancer-promoting genes.

FBXW2 has also been shown to interact with the microRNA, hnRNPK, which is known to play a role in the regulation of gene expression and the expression of cancer

Protein Name: F-box And WD Repeat Domain Containing 2

Functions: Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex

The "FBXW2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXW2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets